Successful pregnancy in a patient with chronic myeloid leukemia under treatment with imatinib

Motohiro Tsuzuki; Youko Inaguma; Kousuke Handa; Akio Hasegawa; Yukiya Yamamoto; Masato Watanabe; Syuichi Mizuta; Fumio Maruyama; Masataka Okamoto; Nobuhiko Emi

doi:10.2169/internalmedicine.48.2084

Successful pregnancy in a patient with chronic myeloid leukemia under treatment with imatinib

Motohiro Tsuzuki, Youko Inaguma, Kousuke Handa, Akio Hasegawa, Yukiya Yamamoto, Masato Watanabe, Syuichi Mizuta, Fumio Maruyama, Masataka Okamoto, Nobuhiko Emi

Research output: Contribution to journal › Article › peer-review

7 Citations (Scopus)

Abstract

Contraception is recommended during imatinib therapy based on the teratogenicity data in rats. However, patients may become pregnant and here we describe a successful pregnancy and labor without any congenital anomaly in a patient with chronic myeloid leukemia (CML) under treatment with imatinib. The patient had received imatinib for 53 months before she became pregnant, with a complete cytogenetic response achieved after 6 months of therapy and a major molecular response (MMR) after 28 months. CML was in MMR at discovery of pregnancy and the fetus had been exposed to imatinib for 5 weeks. Treatment was discontinued, but MMR persisted during gestation.

Original language	English
Pages (from-to)	1433-1435
Number of pages	3
Journal	Internal Medicine
Volume	48
Issue number	16
DOIs	https://doi.org/10.2169/internalmedicine.48.2084
Publication status	Published - 2009
Externally published	Yes

All Science Journal Classification (ASJC) codes

Internal Medicine

Access to Document

10.2169/internalmedicine.48.2084

Cite this

@article{16b2aab768074be9b5186e0783f5d9c2,

title = "Successful pregnancy in a patient with chronic myeloid leukemia under treatment with imatinib",

abstract = "Contraception is recommended during imatinib therapy based on the teratogenicity data in rats. However, patients may become pregnant and here we describe a successful pregnancy and labor without any congenital anomaly in a patient with chronic myeloid leukemia (CML) under treatment with imatinib. The patient had received imatinib for 53 months before she became pregnant, with a complete cytogenetic response achieved after 6 months of therapy and a major molecular response (MMR) after 28 months. CML was in MMR at discovery of pregnancy and the fetus had been exposed to imatinib for 5 weeks. Treatment was discontinued, but MMR persisted during gestation.",

author = "Motohiro Tsuzuki and Youko Inaguma and Kousuke Handa and Akio Hasegawa and Yukiya Yamamoto and Masato Watanabe and Syuichi Mizuta and Fumio Maruyama and Masataka Okamoto and Nobuhiko Emi",

year = "2009",

doi = "10.2169/internalmedicine.48.2084",

language = "English",

volume = "48",

pages = "1433--1435",

journal = "Internal Medicine",

issn = "0918-2918",

publisher = "Japanese Society of Internal Medicine",

number = "16",

}

TY - JOUR

T1 - Successful pregnancy in a patient with chronic myeloid leukemia under treatment with imatinib

AU - Tsuzuki, Motohiro

AU - Inaguma, Youko

AU - Handa, Kousuke

AU - Hasegawa, Akio

AU - Yamamoto, Yukiya

AU - Watanabe, Masato

AU - Mizuta, Syuichi

AU - Maruyama, Fumio

AU - Okamoto, Masataka

AU - Emi, Nobuhiko

PY - 2009

Y1 - 2009

N2 - Contraception is recommended during imatinib therapy based on the teratogenicity data in rats. However, patients may become pregnant and here we describe a successful pregnancy and labor without any congenital anomaly in a patient with chronic myeloid leukemia (CML) under treatment with imatinib. The patient had received imatinib for 53 months before she became pregnant, with a complete cytogenetic response achieved after 6 months of therapy and a major molecular response (MMR) after 28 months. CML was in MMR at discovery of pregnancy and the fetus had been exposed to imatinib for 5 weeks. Treatment was discontinued, but MMR persisted during gestation.

AB - Contraception is recommended during imatinib therapy based on the teratogenicity data in rats. However, patients may become pregnant and here we describe a successful pregnancy and labor without any congenital anomaly in a patient with chronic myeloid leukemia (CML) under treatment with imatinib. The patient had received imatinib for 53 months before she became pregnant, with a complete cytogenetic response achieved after 6 months of therapy and a major molecular response (MMR) after 28 months. CML was in MMR at discovery of pregnancy and the fetus had been exposed to imatinib for 5 weeks. Treatment was discontinued, but MMR persisted during gestation.

UR - https://www.scopus.com/pages/publications/70349485264

UR - https://www.scopus.com/inward/citedby.url?scp=70349485264&partnerID=8YFLogxK

U2 - 10.2169/internalmedicine.48.2084

DO - 10.2169/internalmedicine.48.2084

M3 - Article

C2 - 19687593

AN - SCOPUS:70349485264

SN - 0918-2918

VL - 48

SP - 1433

EP - 1435

JO - Internal Medicine

JF - Internal Medicine

IS - 16

ER -

Successful pregnancy in a patient with chronic myeloid leukemia under treatment with imatinib

Abstract

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Fingerprint

Cite this